Catechol-O-Methyltransferase (COMT) Gene (Val158Met) and Brain-Derived Neurotropic Factor (BDNF) (Val66Met) Genes Polymorphism in Schizophrenia: A Case-Control Study
Objective: The effects of human brain-derived neurotropic factor (BDNF) Val66Met (G>A) and the human Catechol-O-methylTransferase (COMT) Val158Met (G>A) polymorphisms on Schizophrenia (SCZ) risk were evaluated.
Methods: This case control study included 92 SCZ patients and 92 healthy controls (HCs). Genotyping of both variants were conducted using Amplification Refractory Mutation System-Polymerase Chain Reaction (ARMS-PCR).
Results: The findings showed that BDNF Val66Met (G>A) variant increased the risk of SCZ (OR=2.008 95%CI=1.008-4.00, P=0.047, GA vs. GG, OR=3.876 95%CI=1.001-14.925, P=0.049. AA vs. GG, OR=2.272. 95%CI=1.204-4.347, P=0.011, GA+AA vs. GG, OR=2.22 95%CI=1.29-3.82. P=0.005, A vs. G). COMT Val158Met (G>A) polymorphism was not associated with the risk/protective of SCZ.
Conclusion: The results proposed that BDNF Val66Met (G>A) polymorphism may increase the risk of SCZ development and did not support an association between COMT Val158Met (G>A) variant and risk/protective of SCZ. Further studies and different ethnicities are recommended to confirm the findings.
Atakhorrami M, Rahimi-Aliabadi S, Jamshidi J, Moslemi E, Movafagh A, Ohadi M, et al. A genetic variant in CAMKK2 gene is possibly associated with increased risk of bipolar disorder. J Neural Transm (Vienna) 2016; 123: 323-328.
Ghasemvand F, Omidinia E, Salehi Z, Rahmanzadeh S. Relationship between polymorphisms in the proline dehydrogenase gene and schizophrenia risk. Genet Mol Res 2015; 14: 11681-11691.
Omidinia E, Mazar FM, Shahamati P, Kianmehr A, Mohammadi HS. Polymorphism of the CLDN5 gene and Schizophrenia in an Iranian Population. Iran J Public Health 2014; 43: 79-83.
Shifman S, Bronstein M, Sternfeld M, Pisanté-Shalom A, Lev-Lehman E, Weizman A, et al. A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet 2002; 71: 1296-1302.
Norton N, Kirov G, Zammit S, Jones G, Jones S, Owen R, et al. Schizophrenia and functional polymorphisms in the MAOA and COMT genes: no evidence for association or epistasis. Am J Med Genet 2002; 114: 491-496.
Wonodi I, Stine OC, Mitchell BD, Buchanan RW, Thaker GK. Association between Val108/158 Met polymorphism of the COMT gene and schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2003; 120: 47-50.
Zammit S, Jones G, Jones SJ, Norton N, Sanders RD, Milham C, et al. Polymorphisms in the MAOA, MAOB, and COMT genes and aggressive behavior in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2004; 128: 19-20.
González-Castro TB, Hernández-Díaz Y, Juárez-Rojop IE, López-Narváez ML, Tovilla-Zárate CA, Fresan A. The Role of a Catechol-O-Methyltransferase (COMT) Val158Met Genetic Polymorphism in Schizophrenia: A Systematic Review and Updated Meta-analysis on 32,816 Subjects. Neuromolecular Med 2016; 18: 216-231.
Huang E, Zai CC, Lisoway A, Maciukiewicz M, Felsky D, Tiwari AK, et al. Catechol-O-methyltransferase Val158Met polymorphism and clinical response to antipsychotic treatment in schizophrenia and schizo-affective disorder patients: a meta-analysis. Int J Neuropsychopharmacol 2016; 19: pyv132.
Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S, et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 2004; 75: 807-821.
Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 2001; 98: 6917-6922.
Herken H, Erdal ME. Catechol‐O‐methyltransferase gene polymorphism in schizophrenia: evidence for association between symptomatology and prognosis. Psychiatr Genet 2001; 11: 105-109.
Strous RD, Bark N, Woerner M, Lachman HM. Lack of association of functional cathechol-O-methyltransferase gene polymorphism in schizophrenia. Biol Psychiatry 1997; 41: 493-495.
Numata S, Ueno S-i, Iga J-i, Yamauchi K, Hongwei S, Ohta K, et al. Brain-derived neurotrophic factor (BDNF) Val66Met polymorphism in schizophrenia is associated with age at onset and symptoms. Neurosci Lett 2006; 401: 1-5.
Hong C-J, Yu YW-Y, Lin C-H, Tsai S-J. An association study of a brain-derived neurotrophic factor Val66Met polymorphism and clozapine response of schizophrenic patients. Neurosci Lett 2003; 349: 206-208.
Naoe Y, Shinkai T, Hori H, Fukunaka Y, Utsunomiya K, Sakata S, et al. No association between the brain-derived neurotrophic factor (BDNF) Val66Met polymorphism and schizophrenia in Asian populations: evidence from a case–control study and meta-analysis. Neurosci Lett 2007; 415: 108-112.
Watanabe Y, Muratake T, Kaneko N, Nunokawa A, Someya T. No association between the brain-derived neurotrophic factor gene and schizophrenia in a Japanese population. Schizophr Res 2006; 84: 29-35.
Galavi HR, Saravani R, Esmaeilzaei E, Mohamadi A. Interleukin‐6 receptor rs2229238C/T and rs4845625T/C polymorphisms increase the risk of schizophrenia in an Iranian population: A pilot study. Clinical and Experimental Neuroimmunology 2017; 8: 54-59.
Saravani R, Esmaeilzaei E, Noorzehi N, Galavi HR. Melatonin Receptor 1B Gene
Polymorphisms, Haplotypes and Susceptibility to Schizophrenia. Revista Română de Medicină de Laborator 2017; 25.
Mousavi M, Saravani R, Modrek MJ, Shahrakipour M, Sekandarpour S. [Detection of Toxoplasma gondii in Diabetic Patients Using the Nested PCR Assay via RE and B1 Genes (Persian)]. Jundishapur J Microbiol 2016; 9: e29493.
McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiologic reviews. Epidemiol Rev 2008; 30: 67-76 .
Männistö PT, Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 1999; 51: 593-628.
Xiu MH, Hui L, Dang YF, De Hou T, Zhang CX, Zheng YL, et al. Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33:1508-1512.
Neves-Pereira M, Cheung J, Pasdar A, Zhang F, Breen G, Yates P, et al. BDNF gene is a risk factor for schizophrenia in a Scottish population. Mol Psychiatry 2005; 10: 208-212.
Tochigi M, Otowa T, Suga M, Rogers M, Minato T, Yamasue H, et al. No evidence for an association between the BDNF Val66Met polymorphism and schizophrenia or personality traits. Schizophr Res 2006; 87: 45-47.
Kunugi H, Hirasawa H, Kato N, Nabika T, Kobayashi S, Nanko S. Brain-derived neurotrophic factor gene and schizophrenia: polymorphism screening and association analysis. Schizophr Res 2003; 62: 281-283.
Tan YL, Zhou DF, Cao LY, Zou YZ, Wu GY, Zhang XY. Effect of the BDNF Val66Met genotype on episodic memory in schizophrenia. Schizophr Res 2005; 77: 355-356.
Spalletta G, Morris D, Angelucci F, Rubino I, Spoletini I, Bria P, et al. BDNF Val66Met polymorphism is associated with aggressive behavior in schizophrenia. Eur Psychiatry 2010; 25: 311-313.
Daniels J, Williams N, Williams J, Jones L. Cardno AG, Murphy KC, et al. No evidence for allelic association between schizophrenia and a polymorphism determining high or low catechol O-methyltransferase activity. Am J Psychiatry 1996; 153: 268-270.
Chen C-H, Lee Y-R, Chung M-Y, Wei F-C, Koong F-J, Shaw C-K, et al. Systematic mutation analysis of the catechol O-methyltransferase gene as a candidate gene for schizophrenia. Am J Psychiatry 1999; 156: 1273-1275.
Karayiorgou M, Gogos JA, Galke BL, Wolyniec PS, Nestadt G, Antonarakis SE, et al. Identification of sequence variants and
analysis of the role of the catechol-O-methyl-transferase gene in schizophrenia susceptibility. Biol Psychiatry 1998; 43: 425-431.
Wang Y, Fang Y, Shen Y, Xu Q. Analysis of association between the catechol-O-methyltransferase (COMT) gene and negative symptoms in chronic schizophrenia. Psychiatry Res. 2010; 179: 147-150.
Ohmori O, Shinkai T, Kojima H, Terao T, Suzuki T, Mita T, et al. Association study of a functional catechol-O-methyltransferase gene polymorphism in Japanese schizophrenics. Neurosci Lett 1998; 243: 109-112.
Tosato S, Bonetto C, Di Forti M, Collier D, Cristofalo D, Bertani M, et al. Effect of COMT genotype on aggressive behaviour in a community cohort of schizophrenic patients. Neurosci Lett 2011; 495: 17-21.
Sazci A, Ergul E, Kucukali I, Kilic G, Kaya G, Kara I. Catechol-O-methyltransferase gene Val108/158Met polymorphism, and susceptibility to schizophrenia: association is more significant in women. Brain Res Mol Brain Res 2004; 132: 51-56.
|Issue||Vol 12 No 4 (2017)|
|BDNF COMT Schizophrenia Single Nucleotide Polymorphism|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|